{{Chembox
| ImageFile = Mazapertine.svg
| ImageSize = 200px
| IUPACName = Piperidin-1-yl[3-({4-[2-(propan-2-yloxy)phenyl]piperazin-1-yl}methyl)phenyl]methanone
| OtherNames = RWJ-37796
|Section1={{Chembox Identifiers
| CASNo = 134208-17-6
| CASNo_Ref = {{cascite|correct|}}
| UNII = N0X1XW704P
| PubChem = 60820
| ChemSpiderID = 54808
| ChEMBL = 10085
| SMILES = O=C(N1CCCCC1)c2cc(ccc2)CN4CCN(c3ccccc3OC(C)C)CC4
| InChI = 1/C26H35N3O2/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3
| InChIKey = ZKZFPRUSWCYSGT-UHFFFAOYAF
| StdInChI = 1S/C26H35N3O2/c1-21(2)31-25-12-5-4-11-24(25)28-17-15-27(16-18-28)20-22-9-8-10-23(19-22)26(30)29-13-6-3-7-14-29/h4-5,8-12,19,21H,3,6-7,13-18,20H2,1-2H3
| StdInChIKey = ZKZFPRUSWCYSGT-UHFFFAOYSA-N
  }}
|Section2={{Chembox Properties
| C=26 | H=35 | N=3 | O=2
| Appearance = 
| Density = 
| MeltingPt = 
| BoilingPt = 
| Solubility =
  }}
|Section3={{Chembox Hazards
| MainHazards = 
| FlashPt = 
| AutoignitionPt =
  }}
}}

'''Mazapertine''' ('''RWJ-37796''') is an [[antipsychotic]] agent that was developed by [[Johnson & Johnson]] but never marketed.  It exerts its pharmacological effect through affinity for [[Dopamine receptor D2|dopamine D<sub>2</sub>]], [[5-HT1A receptor|serotonin 5-HT<sub>1A</sub>]], and [[Alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptors]].<ref>{{Cite journal 
| last1 = Reitz | first1 = A. B. 
| last2 = Baxter | first2 = E. W. 
| last3 = Codd | first3 = E. E. 
| last4 = Davis | first4 = C. B. 
| last5 = Jordan | first5 = A. D. 
| last6 = Maryanoff | first6 = B. E. 
| last7 = Maryanoff | first7 = C. A. 
| last8 = McDonnell | first8 = M. E. 
| last9 = Powell | first9 = E. T. 
| last10 = Renzi 
| doi = 10.1021/jm970164z | first10 = M. J. 
| last11 = Schott | first11 = M. R. 
| last12 = Scott | first12 = M. K. 
| last13 = Shank | first13 = R. P. 
| last14 = Vaught | first14 = J. L. 
| title = Orally Active Benzamide Antipsychotic Agents with Affinity for Dopamine D2, Serotonin 5-HT1A, and Adrenergic α1Receptors 
| journal = Journal of Medicinal Chemistry 
| volume = 41 
| issue = 12 
| pages = 1997–2009 
| year = 1998 
| pmid = 9622541 
| pmc = 
}}</ref>

Mazapertine is safe and well tolerated when administered orally.<ref>{{Cite journal 
| last1 = Kleinbloesem | first1 = C. H. 
| last2 = Jaquet-Müller | first2 = F. O. 
| last3 = Al-Hamdan | first3 = Y. 
| last4 = Baldauf | first4 = C. 
| last5 = Gisclon | first5 = L. 
| last6 = Wesnes | first6 = K. 
| last7 = Curtin | first7 = C. R. 
| last8 = John Stubbs | first8 = R. 
| last9 = Walker | first9 = S. A. 
| doi = 10.1016/S0009-9236(96)90008-9 
| last10 = Brunner-Ferber | first10 = F. O. 
| title = Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men* 
| journal = Clinical Pharmacology & Therapeutics 
| volume = 59 
| issue = 6 
| pages = 675–685 
| year = 1996 
| pmid = 8681493 
| pmc = 
}}</ref>

[[Structural analog|Analogs]] of mazapertine with [[Conformational isomerism|conformational restriction]] have been prepared and have greater affinity for the [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]].<ref>{{cite journal | doi = 10.1016/S0960-894X(97)00074-7 | title = Hindered rotation congeners of mazapertine: High affinity ligands for the 5-HT1A receptor | year = 1997 | last1 = Baxter | first1 = Ellen W. | last2 = Reitz | first2 = Allen B. | journal = Bioorganic & Medicinal Chemistry Letters | volume = 7 | issue = 7 | pages = 763}}</ref>

==References==
{{reflist}}

[[Category:Antipsychotics]]
[[Category:Piperidines]]
[[Category:Piperazines]]
[[Category:Phenol ethers]]

{{Antipsychotics}}


{{Nervous-system-drug-stub}}